RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/33687470/ below:

Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement

Practice Guideline

. 2021 Mar 9;325(10):962-970. doi: 10.1001/jama.2021.1117. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement Alex H Krist^{1 2}, Karina W Davidson³, Carol M Mangione⁴, Michael J Barry⁵, Michael Cabana⁶, Aaron B Caughey⁷, Esa M Davis⁸, Katrina E Donahue⁹, Chyke A Doubeni¹⁰, Martha Kubik¹¹, C Seth Landefeld¹², Li Li¹³, Gbenga Ogedegbe¹⁴, Douglas K Owens¹⁵, Lori Pbert¹⁶, Michael Silverstein¹⁷, James Stevermer¹⁸, Chien-Wen Tseng^{19 20}, John B Wong²¹

Affiliations

¹ Fairfax Family Practice Residency, Fairfax, Virginia.
² Virginia Commonwealth University, Richmond.
³ Feinstein Institute for Medical Research at Northwell Health, Manhasset, New York.
⁴ University of California, Los Angeles.
⁵ Harvard Medical School, Boston, Massachusetts.
⁶ University of California, San Francisco.
⁷ Oregon Health & Science University, Portland.
⁸ University of Pittsburgh, Pittsburgh.
⁹ University of North Carolina at Chapel Hill.
¹⁰ Mayo Clinic, Rochester, Minnesota.
¹¹ George Mason University, Fairfax, Virginia.
¹² University of Alabama at Birmingham.
¹³ University of Virginia, Charlottesville.
¹⁴ New York University, New York.
¹⁵ Stanford University, Stanford, California.
¹⁶ University of Massachusetts Medical School, Worcester.
¹⁷ Boston University, Boston, Massachusetts.
¹⁸ University of Missouri, Columbia.
¹⁹ University of Hawaii, Honolulu.
²⁰ Pacific Health Research and Education Institute, Honolulu, Hawaii.
²¹ Tufts University School of Medicine, Boston, Massachusetts.

PMID: 33687470
DOI: 10.1001/jama.2021.1117

Item in Clipboard

Practice Guideline

Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement

US Preventive Services Task Force et al. JAMA. 2021.

. 2021 Mar 9;325(10):962-970. doi: 10.1001/jama.2021.1117. Authors US Preventive Services Task Force; Alex H Krist^{1 2}, Karina W Davidson³, Carol M Mangione⁴, Michael J Barry⁵, Michael Cabana⁶, Aaron B Caughey⁷, Esa M Davis⁸, Katrina E Donahue⁹, Chyke A Doubeni¹⁰, Martha Kubik¹¹, C Seth Landefeld¹², Li Li¹³, Gbenga Ogedegbe¹⁴, Douglas K Owens¹⁵, Lori Pbert¹⁶, Michael Silverstein¹⁷, James Stevermer¹⁸, Chien-Wen Tseng^{19 20}, John B Wong²¹ Affiliations

¹ Fairfax Family Practice Residency, Fairfax, Virginia.
² Virginia Commonwealth University, Richmond.
³ Feinstein Institute for Medical Research at Northwell Health, Manhasset, New York.
⁴ University of California, Los Angeles.
⁵ Harvard Medical School, Boston, Massachusetts.
⁶ University of California, San Francisco.
⁷ Oregon Health & Science University, Portland.
⁸ University of Pittsburgh, Pittsburgh.
⁹ University of North Carolina at Chapel Hill.
¹⁰ Mayo Clinic, Rochester, Minnesota.
¹¹ George Mason University, Fairfax, Virginia.
¹² University of Alabama at Birmingham.
¹³ University of Virginia, Charlottesville.
¹⁴ New York University, New York.
¹⁵ Stanford University, Stanford, California.
¹⁶ University of Massachusetts Medical School, Worcester.
¹⁷ Boston University, Boston, Massachusetts.
¹⁸ University of Missouri, Columbia.
¹⁹ University of Hawaii, Honolulu.
²⁰ Pacific Health Research and Education Institute, Honolulu, Hawaii.
²¹ Tufts University School of Medicine, Boston, Massachusetts.

PMID: 33687470
DOI: 10.1001/jama.2021.1117

Item in Clipboard

Abstract

Importance: Lung cancer is the second most common cancer and the leading cause of cancer death in the US. In 2020, an estimated 228 820 persons were diagnosed with lung cancer, and 135 720 persons died of the disease. The most important risk factor for lung cancer is smoking. Increasing age is also a risk factor for lung cancer. Lung cancer has a generally poor prognosis, with an overall 5-year survival rate of 20.5%. However, early-stage lung cancer has a better prognosis and is more amenable to treatment.

Objective: To update its 2013 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the accuracy of screening for lung cancer with low-dose computed tomography (LDCT) and on the benefits and harms of screening for lung cancer and commissioned a collaborative modeling study to provide information about the optimum age at which to begin and end screening, the optimal screening interval, and the relative benefits and harms of different screening strategies compared with modified versions of multivariate risk prediction models.

Population: This recommendation statement applies to adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.

Evidence assessment: The USPSTF concludes with moderate certainty that annual screening for lung cancer with LDCT has a moderate net benefit in persons at high risk of lung cancer based on age, total cumulative exposure to tobacco smoke, and years since quitting smoking.

Recommendation: The USPSTF recommends annual screening for lung cancer with LDCT in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. (B recommendation) This recommendation replaces the 2013 USPSTF statement that recommended annual screening for lung cancer with LDCT in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years.

PubMed Disclaimer

Summary for patients in

Screening for Lung Cancer.
Jin J. Jin J. JAMA. 2021 Mar 9;325(10):1016. doi: 10.1001/jama.2021.1799. JAMA. 2021. PMID: 33687464 No abstract available.